Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

On Jun 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly’s (LLY) Alzheimer's disease drug, donanemab. Eli Lilly gained 2.6% last week and 14.1% past month.The committee said that data from clinical studies on donanemab demonstrated substantial evidence of efficacy and a clinically meaningful slowdown in disease progression for early symptomatic Alzheimer’s patients. Lilly is seeking approval for donanemab for th ...